Knowing that the CD44+ is a commonly used cancer-stem-cell biomarker, our targeted biotin-MBs could be a potent tool to sort cancer stem cells from dissected tumor tissue for use in preclinical experiments and clinical trials. This evidence concerns the gene CD44 and neoplasm.